- Home
- G vs IBRX Comparison
G vs IBRX Comparison
Compare G & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | G | IBRX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | Bermuda | United States |
| Employees | 140000 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 8.2B |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | G | IBRX |
|---|---|---|
| Price | $39.45 | $8.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $42.91 | $14.25 |
| AVG Volume (30 Days) | 1.7M | ★ 13.5M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | 9.82 | ★ 38.71 |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $2,279,438,000.00 | $113,288,000.00 |
| Revenue This Year | $7.02 | $99.98 |
| Revenue Next Year | $7.08 | $108.29 |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $26.85 | $1.95 |
| 52 Week High | $48.64 | $12.43 |
Technical Indicators
Market Signals| Indicator | G | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 43.65 |
| Support Level | $32.99 | $7.71 |
| Resistance Level | $41.84 | $8.51 |
| Average True Range (ATR) | 1.24 | 0.72 |
| MACD | 0.15 | -0.13 |
| Stochastic Oscillator | 65.31 | 17.45 |
Price Performance
Historical ComparisonAbout G Genpact Limited
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.